JP2020536098A5 - - Google Patents

Download PDF

Info

Publication number
JP2020536098A5
JP2020536098A5 JP2020519254A JP2020519254A JP2020536098A5 JP 2020536098 A5 JP2020536098 A5 JP 2020536098A5 JP 2020519254 A JP2020519254 A JP 2020519254A JP 2020519254 A JP2020519254 A JP 2020519254A JP 2020536098 A5 JP2020536098 A5 JP 2020536098A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
patient
composition according
administered
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020519254A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536098A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/052879 external-priority patent/WO2019070478A1/en
Publication of JP2020536098A publication Critical patent/JP2020536098A/ja
Publication of JP2020536098A5 publication Critical patent/JP2020536098A5/ja
Pending legal-status Critical Current

Links

JP2020519254A 2017-10-06 2018-09-26 グリシン脳症を治療するためのベンゾエート含有組成物の使用 Pending JP2020536098A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762569251P 2017-10-06 2017-10-06
US62/569,251 2017-10-06
PCT/US2018/052879 WO2019070478A1 (en) 2017-10-06 2018-09-26 USE OF A BENZOATE-CONTAINING COMPOSITION FOR TREATING GLYCINIC ENCEPHALOPATHY

Publications (2)

Publication Number Publication Date
JP2020536098A JP2020536098A (ja) 2020-12-10
JP2020536098A5 true JP2020536098A5 (enExample) 2021-08-12

Family

ID=65994915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020519254A Pending JP2020536098A (ja) 2017-10-06 2018-09-26 グリシン脳症を治療するためのベンゾエート含有組成物の使用

Country Status (10)

Country Link
US (1) US11304923B2 (enExample)
EP (1) EP3691630A4 (enExample)
JP (1) JP2020536098A (enExample)
KR (1) KR20200065012A (enExample)
CN (1) CN111212637A (enExample)
AU (2) AU2018345244A1 (enExample)
BR (1) BR112020005856A2 (enExample)
CA (1) CA3078609A1 (enExample)
EA (1) EA202090666A1 (enExample)
WO (1) WO2019070478A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020229316A1 (en) * 2019-02-25 2021-09-16 Rush University Medical Center Compositions including cinnamic acid and methods of use thereof
JP2022541021A (ja) * 2019-07-16 2022-09-21 ラッシュ・ユニバーシティ・メディカル・センター 神経変性障害を治療するためのベンゾエート含有組成物の使用
EP4262781A4 (en) * 2020-12-16 2025-02-12 Rush University Medical Center Administration of glycerol tribenzoate and glycerol phenylbutyrate for treatment of neurodegenerative and urea cycle disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2811991A4 (en) * 2012-02-10 2016-03-16 Whitehead Biomedical Inst INHIBITION OF THE GLYCIN CLEAVAGE SYSTEM FOR THE TREATMENT OF CANCER
HUE053671T2 (hu) * 2014-01-17 2021-07-28 Univ Rush Medical Center Gliceril-tribenzoátot tartalmazó készítmény neurodegeneratív rendellenességben történõ alkalmazása

Similar Documents

Publication Publication Date Title
JP2005097323A5 (enExample)
MX2012007410A (es) Compuestos antivirales novedosos.
WO2010103544A3 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
JP2011525911A5 (enExample)
JP2009102342A5 (enExample)
JP2018534348A5 (enExample)
JP2013505205A5 (enExample)
JP2012255026A5 (enExample)
JP2016512248A5 (enExample)
JP2009535352A5 (enExample)
JP2020097577A5 (enExample)
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
JP2012533565A5 (enExample)
JP2024075655A5 (ja) 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用
JP2020536098A5 (enExample)
DE50203456D1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
JP2005528430A5 (enExample)
JP2021520400A (ja) エダラボン医薬組成物
JP2017533211A5 (enExample)
JP2014521641A5 (enExample)
JP2014507475A5 (enExample)
JP2017505811A5 (enExample)
JP2020510045A5 (enExample)
JP2010500284A5 (enExample)
IL272834B2 (en) Amantadine compositions, preparations thereof, and methods of use